PATENT COOPERATION TREATY

m the ERNATIONAL SEARCHING AUTHOR	RITY	O O DAMY SEES	PCT
see form PCT/ISA/220	REO'C	WRITT INTERNATION (P	
applicant's or agent's file reference		FOR FURTHER A See paragraph 2 below	W
nternational application No. PCT/EP2005/000542	International filing date (c 20.01.2005	day/month/year)	Priority date (day/month/year) 21.01.2004
nternational Patent Classification (IPC) or I C07D417/04, C07D417/14, A61K3	both national classification 1/501, A61K31/506, A	and IPC .61P11/00	
□ Box No. IV Lack of unity of Reasoned state applicability; of Box No. VI Certain docurting Box No. VII Certain defection □ Box No. VIII Certain observations. 2. FURTHER ACTION	ment of opinion with regot invention attement under Rule 43 <i>b</i> citations and explanation ments cited at in the international apprations on the international eliminary examination is and Preliminary Examin	gard to novelty, invent is.1(a)(i) with regard to ns supporting such sta oplication onal application s made, this opinion wing Authority ("IPEA")	rill usually be considered to be a . However, this does not apply where
If this opinion is, as provided a submit to the IPEA a written re months from the date of mallin whichever expires later.	ig of Form PCT/ISA/220	a written opinion of the propriate, with amendr or before the expiration	e IPEA, the applicant is invited to ments, before the expiration of three on of 22 months from the priority date,
For further options, see Form 3. For further details, see notes t			
La di		Authorized Officer	- Company Palenton

Name and mailing address of the ISA:

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

Usuelli, A

Telephone No. +49 89 2399-7366



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2005/000542

_					
_	Box N	o. I Basis of the opinion			
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.				
	la	nis opinion has been established on the basis of a translation from the original language into the following nguage , which is the language of a translation furnished for the purposes of international search nder Rules 12.3 and 23.1(b)).			
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:				
	a. type of material:				
		a sequence listing			
		table(s) related to the sequence listing			
	b. forn	nat of material:			
		in written format			
		in computer readable form			
,	of filing/furnishing:				
		contained in the international application as filed.			
		filed together with the international application in computer readable form.			
		furnished subsequently to this Authority for the purposes of search.			
3.	h: C	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto as been filed or furnished, the required statements that the information in the subsequent or additional opies is identical to that in the application as filed or does not go beyond the application as filed, as oppropriate, were furnished.			
4.	. Additional comments:				

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2005/000542

Box No. V Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-14

No:

Inventive step (IS)

Yes: Claims

Claims

1-14

No: Claims

Industrial applicability (IA)

Yes: Claims

1-14

No: Claims

2. Citations and explanations

see separate sheet

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- 1- Reference is made to the following documents cited in the search report:
 - d1: WO 99/64418 A (NOVARTIS AG; NOVARTIS-ERFINDUNGEN
 VERWALTUNGSGESELLSCHAFT MBH; HENG, R) 16 December 1999 (199912-16)
 - d2: WO 03/039451 A (FUJISAWA PHARMACEUTICAL CO., LTD; TSUTSUMI, HIDEO; TABUCHI, SEIICHIRO;) 15 May 2003 (2003-05-15)
 - d3: WO 02/42298 A (NOVARTIS AG; NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH; PRESS,) 30 May 2002 (2002-05-30)

2- Novelty

Present compounds are novel at least on account of the group Y. The requirements of Art. 33.2 are therefore met.

- 3- Inventive step
- 3.1- The applicant has set himself the task of providing novel compounds which exhibit inhibition of A2b receptor activation.

Documents d1 and d3 relate to thiazole derivatives having the same use of present compounds. D2 discloses thiazole derivatives showing greater affinity for the A1 and A2a receptors (cf. page 36). Considering the chemical structures of the compounds disclosed in these documents and their activity, it is considered that d1 represents the closest state of the art.

For the purpose of assessing the inventive step during the international phase, it is accepted that present compounds of formula (I) have the claimed activity, i.e. they inhibit the activation of the A2a receptor.

3.2- Compounds of d1 differ from the compounds of the invention in that the thiazole is substituted in position 5 by a pyridine ring while in the corresponding position, present compounds contain a pyrimidine or pyridazine ring. Despite this similarity, it appears that there are no suggestions in the prior art documents for replacing the pyridine by a

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/EP2005/000542

pyrimidine or pyridazine moiety according to the present group Y. Hence, present compounds are regarded as inventive.